On Friday, Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was -4.56% drop from the session before settling in for the closing price of $2.41. A 52-week range for MREO has been $2.22 – $5.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -40.00%. When this article was written, the company’s average yearly earnings per share was at 20.83%. With a float of $142.66 million, this company’s outstanding shares have now reached $155.15 million.
Let’s determine the extent of company efficiency that accounts for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mereo Biopharma Group Plc ADR (MREO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mereo Biopharma Group Plc ADR stocks. The insider ownership of Mereo Biopharma Group Plc ADR is 8.04%, while institutional ownership is 66.28%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 20.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.97% during the next five years compared to 34.82% growth over the previous five years of trading.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
You can see what Mereo Biopharma Group Plc ADR (MREO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Looking closely at Mereo Biopharma Group Plc ADR (NASDAQ: MREO), its last 5-days average volume was 1.34 million, which is a jump from its year-to-date volume of 1.26 million. As of the previous 9 days, the stock’s Stochastic %D was 28.29%. Additionally, its Average True Range was 0.17.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 3.46%, which indicates a significant decrease from 14.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.99% in the past 14 days, which was lower than the 60.64% volatility it showed in the past 100 days.
However, in the short run, Mereo Biopharma Group Plc ADR’s stock first resistance to watch stands at $2.42. Second resistance stands at $2.55. The third major resistance level sits at $2.62. If the price goes on to break the first support level at $2.23, it is likely to go to the next support level at $2.16. Now, if the price goes above the second support level, the third support stands at $2.03.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
There are 155,146K outstanding shares of the company, which has a market capitalization of 356.84 million. As of now, sales total 10,000 K while income totals -29,470 K. Its latest quarter income was 0 K while its last quarter net income were -15,000 K.
